Neurocrine Biosciences (NBIX) Operating Income: 2010-2021
Historic Operating Income for Neurocrine Biosciences (NBIX) over the last 12 years, with Sep 2021 value amounting to $44.5 million.
- Neurocrine Biosciences' Operating Income rose 200.45% to $44.5 million in Q3 2021 from the same period last year, while for Sep 2021 it was $94.5 million, marking a year-over-year decrease of 32.49%. This contributed to the annual value of $72.3 million for FY2019, which is 95.92% up from last year.
- Per Neurocrine Biosciences' latest filing, its Operating Income stood at $44.5 million for Q3 2021, which was down 29.14% from $62.8 million recorded in Q2 2021.
- Neurocrine Biosciences' 5-year Operating Income high stood at $90.1 million for Q3 2019, and its period low was -$101.0 million during Q1 2019.
- Moreover, its 3-year median value for Operating Income was $46.6 million (2019), whereas its average is $30.2 million.
- Per our database at Business Quant, Neurocrine Biosciences' Operating Income crashed by 283.24% in 2017 and then soared by 1,957.45% in 2019.
- Neurocrine Biosciences' Operating Income (Quarterly) stood at $11.8 million in 2017, then skyrocketed by 84.81% to $21.9 million in 2018, then surged by 123.05% to $48.8 million in 2019, then crashed by 149.17% to -$44.3 million in 2020, then surged by 200.45% to $44.5 million in 2021.
- Its Operating Income was $44.5 million in Q3 2021, compared to $62.8 million in Q2 2021 and $31.5 million in Q1 2021.